Limb salvage or amputation: on the clinical thinking and decision-making of the treatment of severe diabetic foot

doi:10.3877/cma.j.issn.1673-9450.2023.01.002

Abstract

Abstract:

In recent years, although the basic research and clinical treatment of diabetic foot have made great progress, no breakthrough has been made. Limb salvage or amputation is always the perplexity of clinical thinking and the difficulty of clinical treatment decision of severe diabetic foot. Although limb salvage is still the mainstream view and treatment option, amputation does not mean treatment failure. This paper discusses the advantages and disadvantages of the two concepts, arguing that patients with passive amputation often have poor general condition and poor prognosis (death/wound healing of amputation), and proposes that targeted, predictive and proactive amputation should be selected for patients with severe diabetic foot according to the condition and limb function, in order to achieve rapid control of the disease, shorten the length of hospitalization and obtain a better prognosis outcome. At the same time, it is proposes that a multicenter comparative clinical study of the long-term efficacy of the two treatment options should be conducted as soon as possible.

Key words: Diabetic foot, Amputation, Limb salvage, Clinical thinking and decision making

Chiyu Jia, Zexin Zhang, Bin Yin. Limb salvage or amputation: on the clinical thinking and decision-making of the treatment of severe diabetic foot[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(01): 10-15.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2023.01.002

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2023/V18/I01/10

References 44

[1]	Apelqvist J, Bakker K, van Houtum WH, et al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot[J]. Diabetes Metab Res Rev, 2000, 16 Suppl 1: S84-92.
[2]	《多学科合作下糖尿病足防治专家共识(2020版)》编写组. 多学科合作下糖尿病足防治专家共识(2020版)全版[J]. 中华烧伤杂志，2020, 36(8): E01-E52.
[3]	舒斌，陈蕾，祁少海，等. 糖尿病足截肢平面及愈合因素的分析[J/CD]. 中华损伤与修复杂志(电子版), 2010, 5(1): 56-60.
[4]	王爱红，许樟荣，纪立农. 中国城市医院糖尿病截肢的临床特点及医疗费用分析[J]. 中华医学杂志，2012, 92(4): 224-227.
[5]	Wang SY, Liu JF, Huang YP, et al. The Diabetic Foot Amputation Decision-Making Process[J]. Adv Skin Wound Care, 2018, 31(9): 413-420.
[6]	Xu Z, Ran X. Diabetic foot care in China: challenges and strategy[J]. Lancet Diabetes Endocrinol, 2016, 4(4): 297-298.
[7]	赵晨旭，周慧敏. 《中国糖尿病足诊治指南》解读[J]. 中国临床医生杂志，2021, 49(12): 1405-1408.
[8]	Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Res Clin Pract, 2019, 157: 107842.
[9]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志，2021, 13(4): 315-409.
[10]	Lin CW, Armstrong DG, Lin CH, et al. Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period[J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000795.
[11]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志，2021, 37(4): 311-398.
[12]	Schaper NC, van Netten JJ, Apelqvist J, et al. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update)[J]. Diabetes Metab Res Rev, 2020, 36 Suppl 1 (2020): e3266.
[13]	Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine[J]. J Vasc Surg, 2016, 63(2 Suppl): 3S-21S.
[14]	Wang Z, Hasan R, Firwana B, et al. A systematic review and meta-analysis of tests to predict wound healing in diabetic foot[J]. J Vasc Surg, 2016, 63(2 Suppl): 29S-36S.e1-2.
[15]	Yang C, Weng H, Chen L, et al. Transcutaneous oxygen pressure measurement in diabetic foot ulcers: mean values and cut-point for wound healing[J]. J Wound Ostomy Continence Nurs, 2013, 40(6): 585-589.
[16]	Grimaldi V, Schiano C, Casamassimi A, et al. Imaging techniques to evaluate cell therapy in peripheral artery disease: state of the art and clinical trials[J]. Clin Physiol Funct Imaging, 2016, 36(3): 165-178.
[17]	Got I. Transcutaneous oxygen pressure (TcPO₂): advantages and limitations[J]. Diabetes Metab, 1998, 24(4): 379-384.
[18]	Zubair M, Ahmad J. Transcutaneous oxygen pressure (TcPO(2)) and ulcer outcome in diabetic patients: Is there any correlation？[J]. Diabetes Metab Syndr, 2019, 13(2): 953-958.
[19]	Lepäntalo M. The role of the vascular laboratory in the management of major lower limb amputations[J]. Ann Chir Gynaecol, 1988, 77(2): 74-77.
[20]	Armstrong DG, Boulton AJM, Bus SA. Diabetic Foot Ulcers and Their Recurrence[J]. N Engl J Med, 2017, 376(24): 2367-2375.
[21]	Caravaggi C, 王玉珍. 糖尿病足病保肢治疗和改善患者生活质量的新策略[J]. 中华糖尿病杂志，2013, 5(6): 381-382.
[22]	Scatena A, Petruzzi P, Ferrari M, et al. Outcomes of three years of teamwork on critical limb ischemia in patients with diabetes and foot lesions[J]. The international journal of lower extremity wounds, 2012, 11(2012): 113-119.
[23]	Simpson EL, Kearns B, Stevenson MD, et al. Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis[J]. Health Technol Assess, 2014, 18(10): 1-252.
[24]	Shammas NW, Shammas GA, Arikat L, et al. Five-Year Freedom From Target-Lesion Revascularization Using Excimer Laser Ablation Therapy in the Treatment of In-Stent Restenosis of Femoropopliteal Arteries[J]. J Invasive Cardiol, 2017, 29(6): 207-208.
[25]	Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial[J]. Lancet, 2005, 366(9501): 1925-1934.
[26]	Hassanshahi A, Hassanshahi M, Khabbazi S, et al. Adipose-derived stem cells for wound healing[J]. J Cell Physiol, 2019, 234(6): 7903-7914.
[27]	Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus[J]. Cochrane Database Syst Rev, 2014(2): Cd009122.
[28]	Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy[J]. Curr Drug Targets, 2008, 9(1): 14-36.
[29]	Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review[J]. Treat Endocrinol, 2004, 3(3): 173-189.
[30]	Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial[J]. Diabetes Care, 2006, 29(7): 1538-1544.
[31]	Shin S, Kim KJ, Chang HJ, et al. The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial[J]. Diabetes Obes Metab, 2013, 15(2): 185-188.
[32]	Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy[J]. Clin Neurol Neurosurg, 1992, 94(2): 105-111.
[33]	Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy[J]. Nat Med, 1996, 2(6): 703-707.
[34]	Tascini C, Piaggesi A, Tagliaferri E, et al. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy[J]. Diabetes Res Clin Pract, 2011, 94(1): 133-139.
[35]	Tan JS, Friedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation？[J]. Clin Infect Dis, 1996, 23(2): 286-291.
[36]	Rice JB, Desai U, Cummings AK, et al. Burden of diabetic foot ulcers for medicare and private insurers[J]. Diabetes Care, 2014, 37(3): 651-658.
[37]	杜营营，高歌，关小宏，等. 糖尿病足防治及护理进展[J/CD]. 中华损伤与修复杂志(电子版), 2017, 12(5): 389-391.
[38]	Chu YJ, Li XW, Wang PH, et al. Clinical outcomes of toe amputation in patients with type 2 diabetes in Tianjin, China[J]. Int Wound J, 2016, 13(2): 175-181.
[39]	Vadiveloo T, Jeffcoate W, Donnan PT, et al. Amputation-free survival in 17，353 people at high risk for foot ulceration in diabetes: a national observational study[J]. Diabetologia, 2018, 61(12): 2590-2597.
[40]	Weledji EP, Fokam P. Treatment of the diabetic foot - to amputate or not？[J]. BMC Surg, 2014, 14: 83.
[41]	Lipsky BA, Senneville é，Abbas ZG, et al. International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)[J]. Diabetes Metab Res Rev, 2020, 36 Suppl 1: e3280.
[42]	Ramczykowski T, Schildhauer TA. Amputation of the Lower Limb - Treatment and Management[J]. Z Orthop Unfall, 2017, 155(4): 477-498.
[43]	Ashraff S, Siddiqui MA, Santos D, et al. Prediction of stump healing in lower limb amputation: a narrative review[J]. J Wound Care, 2019, 28(Sup 12): S18-S25.
[44]	Brocco E, Ninkovic S, Marin M, et al. Diabetic foot management: multidisciplinary approach for advanced lesion rescue[J]. J Cardiovasc Surg (Torino), 2018, 59(5): 670-684.

Please choose a citation manager

Content to export